Algernon Competitors

OTC Stocks . USA . 
Stock . Algernon Pharmaceuticals
AGNPF Stock  USD 0.05  0.01  11.54%   
Algernon Pharmaceuticals competes with Sino Biopharmaceutica, Defence Therapeutics, Aileron Therapeutics, and Enlivex Therapeutics; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Algernon Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Algernon Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Algernon Pharmaceuticals Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Algernon Pharmaceuticals competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.0510.74
Details
Intrinsic
Valuation
LowRealHigh
0.000.0410.73
Details
Naive
Forecast
LowNextHigh
0.00090.0510.73
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.050.050.06
Details

Algernon Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Algernon Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Algernon and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Algernon Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ENLV
+ 0.45
ALRN
LVCLF
+ 0.33
ENLV
LVCLF
+ 0.27
DTCFF
ENLV
+ 0.23
DTCFF
MRZM
+ 0.22
ENLV
MRZM
+ 0.19
DTCFF
  
High negative correlations   
ENLV
- 0.62
SBHMY
LVCLF
- 0.58
SBHMY
LVCLF
- 0.13
ALRN
DTCFF
- 0.12
SBHMY
ALRN
- 0.08
SBHMY
MRZM
- 0.07
LVCLF

Risk-Adjusted Indicators

There is a big difference between Algernon OTC Stock performing well and Algernon Pharmaceuticals OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Algernon Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
SBHMY  0.64  0.21  0.00  1.46  0.00 
 0.00 
 0.00 
 0.00 
 25.86 
DTCFF  1.04 (0.18) 0.00 (1.46) 0.00 
 0.00 
 0.00 
(2.44)
 25.87 
ALRN  4.30 (0.29) 0.00 (0.38) 0.00 
 0.00 
 8.06 
(8.77)
 41.47 
ENLV  3.79  0.04  0.00  0.16  3.90 
(5.36)
 10.71 
(6.15)
 35.66 
LVCLF  1.99 (0.32) 0.00  0.72  0.00 
 0.00 
 0.00 
 0.00 
 66.02 
MCET  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
HESG  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
MYMX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
MRZM  8.15  1.52  0.03 (0.38) 10.15 
(55.00)
 25.00 
(25.00)
 128.57 
All Fundamental Data

Algernon Pharmaceuticals Competitive Analysis

The better you understand Algernon Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Algernon Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Algernon Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AGNPF SBHMY DTCFF ALRN ENLV LVCLF MYMX MRZM
 11.54 
 0.05 
Algernon
 0.00 
 9.05 
Sino
 0.00 
 0.41 
Defence
 0.93 
 2.12 
Aileron
 0.80 
 1.26 
Enlivex
 18.60 
 0.01 
Living
 0.00 
 0 
Mymetics
 25.00 
 0.03 
Marizyme
Market Volatility
(90 Days Market Risk)
Out of control
Somewhat reliable
Out of control
Slightly risky
Risky
Out of control
Very steady
Out of control
Market Performance
(90 Days Performance)
Very Weak
Modest
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
Quite High
Low
Very High
About Average
Low
Low
Quite High
Below Average
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Fairly Valued
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Buy
Strong Buy
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Buy
Hold
Strong Hold
Hold
Cautious Hold
Hold
Cautious Hold
Current Ratio
1.16 X
1.55 X
0.61 X
6.51 X
15.44 X
17.84 X
0.01 X
1.74 X
Net Asset
8.14 M
60.54 B
719.67 K
106.01 M
36.83 M
4.27 M
7.63 M
66 M
Profit Margin
N/A
0.29 %
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(6.02 M)
19.87 B
(7.32 M)
(15.61 M)
(28.22 M)
(2.38 M)
(1.96 M)
(10.83 M)
Current Valuation
3.03 M
10.34 B
60.32 M
28.67 M
3.97 M
12.53 M
83.16 M
17.35 M
Price To Book
1.02 X
2.53 X
36.71 X
0.92 X
1.04 X
6.96 X
N/A
0.37 X
Operating Margin
N/A
0.16 %
N/A
N/A
N/A
(428.70) %
(1.76) %
(180.85) %
Five Year Return
N/A
0.99 %
N/A
N/A
N/A
N/A
N/A
N/A
Retained Earnings
N/A
N/A
N/A
(288.52 M)
(112.09 M)
(67 M)
(81.98 M)
N/A
Current Asset
N/A
N/A
N/A
3.43 M
6 M
6 M
1.38 M
N/A
Beta
0.32
0.51
N/A
2.34
1.11
0.27
0.24
0.36
Number Of Employees
2
25.55 K
4
15
N/A
15
9
11
Shares Outstanding
2.41 M
940.69 M
37.85 M
21.67 M
21.99 M
1.29 B
303.76 M
10.13 M
Cash Flow From Operations
(2.91 M)
5.37 B
(6.04 M)
(19.81 M)
(23.52 M)
(2.04 M)
(1.7 M)
(5.79 M)
Annual Yield
N/A
0.03 %
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
N/A
5.21 B
N/A
48 K
1.03 M
228.44 K
162 K
495.32 K
Return On Equity
-1.09
0.29
-4.15
-0.44
-0.61
-0.72
N/A
-0.5
Z Score
N/A
1.2
-33.0
N/A
N/A
5.4
-1.4
6.0
Return On Asset
-0.53
0.0451
-1.79
-0.26
-0.27
-0.31
-0.14
-0.15
Book Value Per Share
1.86 X
32.70 X
(0.03) X
1.41 X
1.62 X
0 X
(0.21) X
1.00 X
Number Of Shares Shorted
N/A
N/A
N/A
178.8 K
214.77 K
N/A
N/A
N/A
Current Liabilities
N/A
N/A
N/A
459 K
671.32 K
1000 K
51.24 M
N/A
Total Asset
8.14 M
60.54 B
719.67 K
106.01 M
36.83 M
4.27 M
7.63 M
66 M
Debt To Equity
N/A
0.31 %
N/A
0 %
0.08 %
0.10 %
N/A
0.07 %
Last Dividend Paid
N/A
0.083
N/A
N/A
N/A
N/A
N/A
N/A
Short Ratio
N/A
N/A
N/A
3.47 X
0.56 X
N/A
N/A
N/A
Target Price
N/A
N/A
N/A
13.0
9.5
N/A
N/A
N/A
Shares Owned By Institutions
14.73 %
N/A
N/A
28.47 %
18.80 %
N/A
N/A
N/A
Market Capitalization
3.96 M
10.88 B
143.45 M
46.37 M
27.71 M
9.81 M
5.47 M
5.07 M
Price To Earning
N/A
8.95 X
N/A
(0.31) X
(11.97) X
(31.67) X
(2.40) X
N/A
Price To Earnings To Growth
N/A
0.53 X
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
0.41 X
N/A
N/A
N/A
5,587 X
12.17 X
133.06 X
Net Income
(6.05 M)
14.61 B
(7.34 M)
(15.73 M)
(29.07 M)
(1.96 M)
(4.73 M)
(11 M)
Earnings Per Share
(2.28) X
1.15 X
(0.15) X
(2.88) X
(0.98) X
(0) X
(0.02) X
(0.39) X
Shares Owned By Insiders
1.70 %
N/A
5.26 %
0.60 %
5.73 %
33.99 %
54.90 %
2.04 %
Revenue
N/A
26.86 B
N/A
N/A
N/A
3.4 K
3 K
210.28 K
Working Capital
N/A
N/A
N/A
13.88 M
27.7 M
5 M
(49.86 M)
N/A
Cash And Equivalents
872.84 K
15.67 B
506.7 K
32.38 M
62.48 M
4.24 M
350 K
2.04 M
Cash Per Share
0.44 X
16.96 X
0.01 X
0.36 X
3.40 X
N/A
N/A
0.05 X
Gross Profit
N/A
21.53 B
N/A
(17.01 M)
N/A
3.4 K
(545 K)
129.93 K
Day Typical Price
0.0482
9.05
0.41
2.09
1.26
0.0051
0.001
0.03
Accumulation Distribution
1840.06
N/A
N/A
21272.69
11365.12
N/A
N/A
N/A
Daily Balance Of Power
(0.92)
0.0
0.0
(0.06)
0.1429
9.2 T
0.0
(9,223,372,036,855)
Period Momentum Indicator
(0.01)
N/A
N/A
(0.02)
0.01
8.0E-4
N/A
(0.01)
Rate Of Daily Change
0.88
1.0
1.0
0.99
1.01
1.19
1.0
0.75
Day Median Price
0.0493
9.05
0.41
2.08
1.25
0.0051
0.001
0.03
Price Action Indicator
(0.01)
N/A
N/A
0.035
0.01
4.0E-4
N/A
(0.01)
Relative Strength Index
46.86
69.02
52.63
32.37
40.21
26.34
N/A
49.02
Coefficient Of Variation
(3,210)
1132.0
(2,085)
(2,914)
4021.31
(2,408)
N/A
1675.06
Mean Deviation
6.98
0.6415
1.04
4.3
3.79
1.99
N/A
8.15
Jensen Alpha
(0.34)
0.2053
(0.18)
(0.29)
0.0395
(0.32)
N/A
1.52
Total Risk Alpha
(2.01)
(0.19)
(0.68)
(1.19)
(0.78)
(1.80)
N/A
(1.97)
Sortino Ratio
N/A
N/A
N/A
N/A
0.0044
N/A
N/A
0.0328
Downside Variance
N/A
N/A
N/A
N/A
18.49
N/A
N/A
1042.07
Standard Deviation
10.52
2.64
3.22
6.13
5.76
8.96
N/A
19.82
Kurtosis
1.97
57.69
15.33
6.02
4.58
46.58
N/A
12.33
Potential Upside
16.58
N/A
N/A
8.06
10.71
N/A
N/A
25.0
Treynor Ratio
(16.32)
1.46
(1.46)
(0.38)
0.1627
0.7228
N/A
(0.38)
Maximum Drawdown
55.53
25.86
25.87
41.47
35.66
66.02
N/A
128.57
Variance
110.69
6.94
10.39
37.63
33.2
80.28
N/A
392.85
Market Risk Adjusted Performance
(16.31)
1.47
(1.45)
(0.37)
0.1727
0.7328
N/A
(0.37)
Risk Adjusted Performance
(0.01)
0.0711
(0.03)
(0.02)
0.0267
(0.02)
N/A
0.0528
Skewness
0.7226
7.21
(0.39)
1.43
1.58
(5.81)
N/A
2.57
Semi Deviation
N/A
N/A
N/A
N/A
3.9
N/A
N/A
10.15
Information Ratio
(0.04)
0.0411
(0.09)
(0.05)
0.0033
(0.06)
N/A
0.0534
Value At Risk
(15.66)
N/A
(2.44)
(8.77)
(6.15)
N/A
N/A
(25.00)
Expected Short fall
N/A
N/A
N/A
N/A
(5.36)
N/A
N/A
(55.00)
Downside Deviation
N/A
N/A
N/A
N/A
4.3
N/A
N/A
32.28
Semi Variance
N/A
N/A
N/A
N/A
15.19
N/A
N/A
103.0

Algernon Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Algernon Pharmaceuticals Competition

Algernon Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Algernon Pharmaceuticals in relation to its competition. Algernon Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Algernon Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Algernon Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Algernon Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Algernon Pharmaceuticals position

In addition to having Algernon Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Healthcare Funds Thematic Idea Now

Healthcare Funds
Healthcare Funds Theme
Funds or Etfs investing in medical and healthcare goods or services as well as hospital management or maintenance organizations. The Healthcare Funds theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Funds Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Algernon OTC Stock

Algernon Pharmaceuticals financial ratios help investors to determine whether Algernon OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Algernon with respect to the benefits of owning Algernon Pharmaceuticals security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY